Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy

  • Roura, Santiago
  • Gálvez-Montón, Carolina
  • Gonzalo-Calvo, David de
  • Gámez Valero, Ana
  • Gastelurrutia, Paloma
  • Revuelta-López, Elena
  • Prat-Vidal, Cristina
  • Soler-Botija, Carolina
  • Llucià‐Valldeperas, Aida
  • Perea‐Gil, Isaac
  • Iborra‐Egea, Oriol
  • Borràs, Francesc E.
  • Lupón, Josep
  • Llorente-Cortés, Vicenta
  • Bayés Genís, Antoni
Idiopathic dilated cardiomyopathy (IDCM) is a frequent cause of heart transplantation. Potentially valuable blood markers are being sought, andlow-density lipoprotein receptor-related protein 1 (LRP1) has been linked to the underlying molecular basis of the disease. This study comparedcirculating levels of soluble LRP1 (sLRP1) in IDCM patients and healthy controls and elucidated whether sLRP1 is exported out of the myocardiumthrough extracellular vesicles (EVs) to gain a better understanding of the pathogenesis of the disease. LRP1achain expression was analysed insamples collected from the left ventricles of explanted hearts using immunohistochemistry. sLRP1 concentrations were determined in platelet-freeplasma by enzyme-linked immunosorbent assay. Plasma-derived EVs were extracted by size-exclusion chromatography (SEC) and characterizedby nanoparticle tracking analysis and cryo-transmission electron microscopy. The distributions of vesicular (CD9, CD81) and myocardial (caveolin-3) proteins and LRP1achain were assessed in SEC fractions by flow cytometry. LRP1achain was preferably localized to blood vessels in IDCMcompared to control myocardium. Circulating sLRP1 was increased in IDCM patients. CD9- and CD81-positive fractions enriched with membranevesicles with the expected size and morphology were isolated from both groups. The LRP1achain was not present in these SEC fractions, whichwere also positive for caveolin-3. The increase in circulating sLRP1 in IDCM patients may be clinically valuable. Although EVs do not contribute tohigher sLRP1 levels in IDCM, a comprehensive analysis of EV content would provide further insights into the search for novel blood markers, This work was supported by grants from the Ministerio de Educación y Ciencia (SAF2014-59892-R), the Ministerio de Econom ıa yCompetitividad (Juan de la Cierva, JCI-2012-14025), Fundacio La MARATO de TV3 (201502, 201516, 201521_10), the Fundaci o Daniel Bravo Andreu, the Sociedad Española de Cardiología, the Societat Catalana de Cardiologia, the Generalitat de Catalunya (SGR 2014,CERCA Programme), and the Fundacio Bancaria La Caixa. This workwas also funded by the Red de Terapia Celular–TerCel (RD16/0011/0006), the CIBER Cardiovascular–(CB16/11/00403) and Fondo deInvestigaci on Sanitaria, Instituto de Salud Carlos III (FIS PI14/01682,FIS PI14/01729 and CD14/00109) as part of the Plan Nacional deI+D+I cofounded by ISCIII-Sudirecci on General de Evaluaci on y elFondo Europeo de Desarrollo Regional (FEDER), Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure

  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Martínez, Jaume Barallat
  • Pastor Ferrer, Maria Cruz
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Zamora, Elisabet|||0000-0001-5317-7481
  • Sanchis, Juan|||0000-0003-0797-8709
  • Rosés, Josep Lupón
Despite advances in pharmacologic therapy and devices, patients with heart failure (HF) continue to have significant rehospitalization rates and risk prediction remains challenging. We sought to explore the value of a multi-biomarker panel [including NT-proBNP, high-sensitivity cardiac troponin T (hs-TnT), and ST2] on top of clinical assessment for long-term prediction of recurrent hospitalizations in HF. NT-proBNP, hs-TnT, and ST2 (suppression of tumorigenicity-2) levels were measured in 891 consecutive ambulatory HF patients. The independent association between the multi-biomarker panel and recurrent hospitalizations was assessed through a multivariable negative binomial regression and expressed as incidence rates ratios. McFadden pseudo- R 2 and goodness-of-fit measures were also used. The total number of unplanned hospitalizations [all-cause, cardiovascular (CV)-, and HF-related] were selected as the primary endpoints. At a mean follow-up of 4.2 ± 2.1 years, 1623 all-cause hospitalizations in 498 patients (55.9%), 710 CV-related hospitalizations in 331 patients (37.2%), and 444 HF-related hospitalizations in 214 patients (24.1%) were registered. The crude incidence of all-cause, CV-, and HF-related recurrent hospitalizations was significantly higher for patients with the multi-biomarker panel above the cut-point (hs-TnT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction

  • Bobi, Joaquim|||0000-0002-9026-5226
  • Solanes, Núria
  • Fernández-Jiménez, Rodrigo
  • Galán-Arriola, Carlos
  • Dantas, A. P.|||0000-0001-8514-4094
  • Fernández-Friera, Leticia
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Rigol-Monzó, Elisabet
  • Agüero, Jaume|||0000-0001-7416-871X
  • Ramírez, José
  • Roqué, Mercè
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sánchez González, Javier|||0000-0003-1427-3870
  • García-Álvarez, Ana|||0000-0002-1718-2424
  • Sabaté, Manel
  • Rudilla, F..
  • Ibañez, Borja|||0000-0002-5036-254X
  • Rigol, Montserrat
Autologous adipose tissue-derived mesenchymal stem cells (s) therapy is a promising strategy to improve post-myocardial infarction outcomes. In a porcine model of acute myocardial infarction, we studied the long-term effects and the mechanisms involved in allogeneic s administration on myocardial performance. Thirty-eight pigs underwent 50 minutes of coronary occlusion; the study was completed in 33 pigs. After reperfusion, allogeneic s or culture medium (vehicle) were intracoronarily administered. Follow-ups were performed at short (2 days after acute myocardial infarction vehicle-treated, n=10; s-treated, n=9) or long term (60 days after acute myocardial infarction vehicle-treated, n=7; s-treated, n=7). At short term, infarcted myocardium analysis showed reduced apoptosis in the s-treated animals (48.6±6% versus 55.9±5.7% in vehicle; P =0.017); enhancement of the reparative process with up-regulated vascular endothelial growth factor, granulocyte macrophage colony-stimulating factor, and stromal-derived factor-1α gene expression; and increased M2 macrophages (67.2±10% versus 54.7±10.2% in vehicle; P =0.016). In long-term groups, increase in myocardial perfusion at the anterior infarct border was observed both on day-7 and day-60 cardiac magnetic resonance studies in s-treated animals, compared to vehicle (87.9±28.7 versus 57.4±17.7 mL/min per gram at 7 days; P =0.034 and 99±22.6 versus 43.3±14.7 22.6 mL/min per gram at 60 days; P =0.0001, respectively). At day 60, higher vascular density was detected at the border zone in the s-treated animals (118±18 versus 92.4±24.3 vessels/mm 2 in vehicle; P =0.045). Cardiac magnetic resonance-measured left ventricular ejection fraction of left ventricular volumes was not different between groups at any time point. In this porcine acute myocardial infarction model, allogeneic s-based therapy was associated with increased cardioprotective and reparative mechanisms and with better cardiac magnetic resonance-measured perfusion. No effect on left ventricular volumes or ejection fraction was observed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extracellular vesicles do not contribute to higher circulating levels of soluble 1 in idiopathic dilated cardiomyopathy

  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Valero, Ana Gámez
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Soler Botija, Carolina
  • Llucià-Valldeperas, Aida
  • Perea Gil, Isaac
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Lupón, Josep|||0000-0002-5601-9611
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Idiopathic dilated cardiomyopathy () is a frequent cause of heart transplantation. Potentially valuable blood markers are being sought, and low-density lipoprotein receptor-related protein 1 (1) has been linked to the underlying molecular basis of the disease. This study compared circulating levels of soluble 1 (1) in patients and healthy controls and elucidated whether 1 is exported out of the myocardium through extracellular vesicles (s) to gain a better understanding of the pathogenesis of the disease. 1 α chain expression was analysed in samples collected from the left ventricles of explanted hearts using immunohistochemistry. 1 concentrations were determined in platelet-free plasma by enzyme-linked immunosorbent assay. Plasma-derived s were extracted by size-exclusion chromatography () and characterized by nanoparticle tracking analysis and cryo-transmission electron microscopy. The distributions of vesicular (9, 81) and myocardial (caveolin-3) proteins and 1 α chain were assessed in fractions by flow cytometry. 1 α chain was preferably localized to blood vessels in compared to control myocardium. Circulating 1 was increased in patients. 9- and 81-positive fractions enriched with membrane vesicles with the expected size and morphology were isolated from both groups. The 1 α chain was not present in these fractions, which were also positive for caveolin-3. The increase in circulating 1 in patients may be clinically valuable. Although s do not contribute to higher 1 levels in , a comprehensive analysis of content would provide further insights into the search for novel blood markers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unravelling the effects of mechanical physiological conditioning on cardiac adipose tissue-derived progenitor cells in vitro and in silico

  • Llucià-Valldeperas, Aida
  • Bragos, Ramon|||0000-0002-1373-1588
  • Soler Botija, Carolina
  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Perea Gil, Isaac
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Mechanical conditioning is incompletely characterized for stimulating therapeutic cells within the physiological range. We sought to unravel the mechanism of action underlying mechanical conditioning of adipose tissue-derived progenitor cells (ATDPCs), both in vitro and in silico. Cardiac ATDPCs, grown on 3 different patterned surfaces, were mechanically stretched for 7 days at 1 Hz. A custom-designed, magnet-based, mechanical stimulator device was developed to apply ~10% mechanical stretching to monolayer cell cultures. Gene and protein analyses were performed for each cell type and condition. Cell supernatants were also collected to analyze secreted proteins and construct an artificial neural network. Gene and protein modulations were different for each surface pattern. After mechanostimulation, cardiac ATDPCs increased the expression of structural genes and there was a rising trend on cardiac transcription factors. Finally, secretome analyses revealed upregulation of proteins associated with both myocardial infarction and cardiac regeneration, such as regulators of the immune response, angiogenesis or cell adhesion. To conclude, mechanical conditioning of cardiac ATDPCs enhanced the expression of early and late cardiac genes in vitro. Additionally, in silico analyses of secreted proteins showed that mechanical stimulation of cardiac ATDPCs was highly associated with myocardial infarction and repair.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Telomere attrition in heart failure, a flow-FISH longitudinal analysis of circulating monocytes

  • Teubel, Iris
  • Elchinova, Elena Georgieva
  • Roura, Santiago|||0000-0003-4063-9661
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Moliner, P.|||0000-0002-5511-8597
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cross-sectional investigations report shorter telomeres in patients with heart failure (HF); however, no studies describe telomere length (TL) trajectory and its relationship with HF progression. Here we aimed to investigate telomere shortening over time and its relationship to outcomes. Our study cohort included 101 ambulatory patients with HF. Blood samples were collected at baseline (n = 101) and at the 1-year follow-up (n = 54). Using flow-FISH analysis of circulating monocytes, we simultaneously measured three monocyte subsets-classical (CD14 ++ CD16 -), intermediate (CD14 ++ CD16 +), and nonclassical (CD14 + CD16 ++)-and their respective TLs based on FITC-labeled PNA probe hybridization. The primary endpoints were all-cause death and the composite of all-cause death or HF-related hospitalization, assessed at 2.3 ± 0.6 years. All statistical analyses were executed by using the SPSS 15.0 software, and included Student's t test and ANOVA with post hoc Scheffe analysis, Pearson or Spearman rho correlation and univariate Cox regression when applicable. We found high correlations between TL values of different monocyte subsets: CD14 ++ CD16 + vs. CD14 ++ CD16 -, R = 0.95, p < 0.001; CD14 ++ CD16 + vs. CD14 + CD16 ++, R = 0.90, p < 0.001; and CD14 ++ CD16 - vs. CD14 + CD16 ++, R = 0.89, p < 0.001. Mean monocyte TL exhibited significant attrition from baseline to the 1-year follow-up (11.1 ± 3.3 vs. 8.3 ± 2.1, p < 0.001). TL did not significantly differ between monocyte subsets at either sampling time-point (all p values.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction

  • Cediel, Germán|||0000-0001-9667-7507
  • Rueda, Ferran|||0000-0001-5464-4870
  • Oxvig, Claus
  • Oliveras, Teresa
  • Labata, Carlos|||0000-0002-4505-0787
  • De Diego, Oriol|||0000-0002-8476-7094
  • Ferrer Massot, Marc|||0000-0003-0046-1301
  • Aranda-Nevado, M. Cruz
  • Serra-Gregori, Judith
  • Núñez, Julio|||0000-0003-1672-7119
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
The aim of the present study was to evaluate the prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in patients with ST-segment elevation myocardial infarction (STEMI). Observational cohort study performed in 1085 consecutive STEMI patients treated with early reperfusion between February 2011 and August 2014. Stanniocalcin-2, PAPP-A, and IGFBP-4 were measured using state-of-the art immunoassays. The primary outcome was the composite endpoint of all-cause mortality and readmission due to heart failure (HF). Median follow-up was 3.3 years (IQR 1.0-3.7), during which 176 patients (16.2%) presented a composite endpoint. Multivariable cox regression analysis revealed that Stanniocalcin-2 (HR 2.06; 95% CI 1.13-3.75; p = 0.018), IGFBP-4 (HR 1.73; 95% CI 1.14-2.64; p = 0.010), Killip-Kimball class III-IV (HR 1.40; 95% CI 1.13-1.74; p = 0.002), NT-ProBNP (HR 1.21; 95% CI 1.07-1.37; p = 0.002), age (HR 1.06; 95% CI 1.04-1.08; p < 0.001) and left ventricular ejection fraction (HR 0.97; 95% CI 0.95-0.98; p < 0.001) were independent predictors of the composite endpoint. A model containing Stanniocalcin-2 and IGFBP-4 on top of clinical variables significantly improved C-index discrimination (p = 0.036). Stanniocalcin-2 was also identified as independent predictor of all-cause mortality (HR 2.23; 95% CI 1.16-4.29; p = 0.017) and readmission due to HF (HR 3.42; 95% CI 1.22-9.60; p = 0.020). In STEMI patients, Stanniocalcin-2 and IGFBP-4 emerged as independent predictors of all-cause death and readmission due to HF. The Stanniocalcin-2/PAPP-A/IGFBP-4 axis exhibits a significant role in STEMI risk stratification.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Cell-Enriched Engineered Myocardial Graft Limits Infarct Size and Improves Cardiac Function

  • Perea Gil, Isaac
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Rudilla, F..
  • Llucià-Valldeperas, Aida
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Díaz-Güemes, Idoia
  • Crisóstomo, Verónica|||0000-0003-1740-7029
  • Sánchez Margallo, Francisco Miguel|||0000-0003-2138-988X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Myocardial infarction (MI) remains a dreadful disease around the world, causing irreversible sequelae that shorten life expectancy and reduce quality of life despite current treatment. Here, the authors engineered a cell-enriched myocardial graft, composed of a decellularized myocardial matrix refilled with adipose tissue-derived progenitor cells (EMG-ATDPC). Once applied over the infarcted area in the swine MI model, the EMG-ATDPC improved cardiac function, reduced infarct size, attenuated fibrosis progression, and promoted neovascularization of the ischemic myocardium. The beneficial effects exerted by the EMG-ATDPC and the absence of identified adverse side effects should facilitate its clinical translation as a novel MI therapy in humans.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Pujal, Josep Maria
  • Aran, Gemma|||0000-0003-2005-8843
  • Sanjurjo, Lucía|||0000-0003-4006-8010
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
Undesired immune responses have drastically hampered outcomes after allogeneic organ transplantation and cell therapy, and also lead to inflammatory diseases and autoimmunity. Umbilical cord mesenchymal stem cells (UCMSCs) have powerful regenerative and immunomodulatory potential, and their secreted extracellular vesicles (EVs) are envisaged as a promising natural source of nanoparticles to increase outcomes in organ transplantation and control inflammatory diseases. However, poor EV preparations containing highly-abundant soluble proteins may mask genuine vesicular-associated functions and provide misleading data. Here, we used Size-Exclusion Chromatography (SEC) to successfully isolate EVs from UCMSCs-conditioned medium. These vesicles were defined as positive for CD9, CD63, CD73 and CD90, and their size and morphology characterized by NTA and cryo-EM. Their immunomodulatory potential was determined in polyclonal T cell proliferation assays, analysis of cytokine profiles and in the skewing of monocyte polarization. In sharp contrast to the non-EV containing fractions, to the complete conditioned medium and to ultracentrifuged pellet, SEC-purified EVs from UCMSCs inhibited T cell proliferation, resembling the effect of parental UCMSCs. Moreover, while SEC-EVs did not induce cytokine response, the non-EV fractions, conditioned medium and ultracentrifuged pellet promoted the secretion of pro-inflammatory cytokines by polyclonally stimulated T cells and supported Th17 polarization. In contrast, EVs did not induce monocyte polarization, but the non-EV fraction induced CD163 and CD206 expression and TNF-α production in monocytes. These findings increase the growing evidence confirming that EVs are an active component of MSC's paracrine immunosuppressive function and affirm their potential for therapeutics in nanomedicine. In addition, our results highlight the importance of well-purified and defined preparations of MSC-derived EVs to achieve the immunosuppressive effect.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Noninvasive Assessment of an Engineered Bioactive Graft in Myocardial Infarction: Impact on Cardiac Function and Scar Healing

  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bragos, Ramon|||0000-0002-1373-1588
  • Soler Botija, Carolina
  • Díaz-Güemes, Idoia
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Crisóstomo, Verónica|||0000-0003-1740-7029
  • Sánchez Margallo, Francisco Miguel|||0000-0003-2138-988X
  • Llucià-Valldeperas, Aida
  • Bogónez-Franco, Paco|||0000-0002-5364-231X
  • Perea Gil, Isaac
  • Rudilla, F..
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cardiac tissue engineering, which combines cells and biomaterials, is promising for limiting the sequelae of myocardial infarction (MI). We assessed myocardial function and scar evolution after implanting an engineered bioactive impedance graft (EBIG) in a swine MI model. The EBIG comprises a scaffold of decellularized human pericardium, green fluorescent protein-labeled porcine adipose tissue-derived progenitor cells (pATPCs), and a customized-design electrical impedance spectroscopy (EIS) monitoring system. Cardiac function was evaluated noninvasively by using magnetic resonance imaging (MRI). Scar healing was evaluated by using the EIS system within the implanted graft. Additionally, infarct size, fibrosis, and inflammation were explored by histopathology. Upon sacrifice 1 month after the intervention, MRI detected a significant improvement in left ventricular ejection fraction (7.5%64.9% vs. 1.4%63.7%; p = .038) and stroke volume (11.565.9 ml vs. 364.5 ml; p = .019) in EBIG-treated animals. Noninvasive EIS data analysis showed differences in both impedance magnitude ratio (20.02 6 0.04 per day vs. 20.48 6 0.07 per day; p = .002) and phase angle slope (20.18°60.24° per day vs.23.52°60.84° per day; p = .004) in EBIG compared with control animals. Moreover, in EBIG-treated animals, the infarct size was 48% smaller (3.4%60.6% vs. 6.5%61%; p = .015), less inflammation was found by means of CD25+ lymphocytes (0.65 6 0.12 vs. 1.26 6 0.2; p = .006), and a lower collagen I/III ratio was detected (0.4960.06 vs. 1.6660.5; p = .019). An EBIG composed of acellular pericardium refilled with pATPCs significantly reduced infarct size and improved cardiac function in a preclinical model of MI. Noninvasive EIS monitoring was useful for tracking differential scar healing in EBIG-treated animals, which was confirmed by less inflammation and altered collagen deposit.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mesenchymal stem cells induce expression of cD73 in human monocytes in vitro and in a swine model of myocardial infarction in vivo

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
The ectoenzymes CD39 and CD73 regulate the purinergic signaling through the hydrolysis of adenosine triphosphate (ATP)/ADP to AMP and to adenosine (Ado), respectively. This shifts the pro-inflammatory milieu induced by extracellular ATP to the anti- inflammatory regulation by Ado. Mesenchymal stem cells (MSCs) have potent immunomodulatory capabilities, including monocyte modulation toward an anti-inflammatory phenotype aiding tissue repair. In vitro, we observed that human cardiac adipose tissue-derived MSCs (cATMSCs) and umbilical cord MSCs similarly polarize monocytes toward a regulatory M2 phenotype, which maintained the expression of CD39 and induced expression of CD73 in a cell contact dependent fashion, correlating with increased functional activity. In addition, the local treatment with porcine cATMSCs using an engineered bioactive graft promoted the in vivo CD73 expression on host monocytes in a swine model of myocardial infarction. Our results suggest the upregulation of ectonucleotidases on MSC-conditioned monocytes as an effective mechanism to amplify the long-lasting immunomodulatory and healing effects of MSCs delivery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Determination of HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in heart failure patients

  • Rudilla, Francesc|||0000-0002-3099-067X
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Enrich, Emma|||0000-0001-9183-1333
  • Campos, Eva
  • Lupón, Josep|||0000-0002-5601-9611
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Querol, Sergi|||0000-0002-1105-8633
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Aims: Cell therapy can be used to repair functionally impaired organs and tissues in humans. Although autologous cells have an immunological advantage, it is difficult to obtain high cell numbers for therapy. Well-characterized banks of cells with human leukocyte antigens (HLA) that are representative of a given population are thus needed. The present study investigates the HLA allele and haplotype frequencies in a cohort of heart failure (HF) patients. Methods and results: We carried out the HLA typing and the allele and haplotype frequency analysis in 247 ambulatory HF patients. We determined HLA class I (A, B, and C) and class II (DRB1 and DQB1) using next-generation sequencing technology. The allele frequencies were obtained using Python for Population Genomics (PyPop) software, and HLA haplotypes were estimated using HaploStats. A total of 30 HLA-A, 56 HLA-B, 23 HLA-C, 36 HLA-DRB1, and 15 HLA-DQB1 distinct alleles were identified within the studied cohort. The genotype frequencies of all five HLA loci were in Hardy-Weinberg equilibrium. We detected differences in HLA allele frequencies among patients when the etiological cause of HF was considered. There were a total of 494 five-loci haplotypes, five of which were present six or more times. Moreover, the most common estimated HLA haplotype was HLA-A*01:01, HLA-B*08:01, HLA-C*07:01, HLA-DRB1*03:01, and HLA-DQB1*02:01 (6.07% haplotype frequency per patient). Remarkably, the 11 most frequent haplotypes would cover 31.17% of the patients of the cohort in need of allogeneic cell therapy. Conclusions: Our findings could be useful for improving allogeneic cell administration outcomes without concomitant immunosuppression.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Heart failure and diabetes, metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology

  • Maack, Christoph
  • Lehrke, Michael
  • Backs, Johannes|||0000-0002-2322-2699
  • Heinzel, Frank R.
  • Hulot, Jean-Sébastien
  • Marx, Nikolaus
  • Paulus, Walter J.
  • Rossignol, Patrick
  • Taegtmeyer, Heinrich
  • Bauersachs, Johann|||0000-0002-9341-117X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Brutsaert, Dirk
  • Bugger, Heiko
  • Clarke, Kieran
  • Cosentino, Francesco
  • De Keulenaer, Gilles
  • Dei Cas, Alessandra
  • González, Arantxa|||0000-0001-5986-6528
  • Huelsmann, Martin
  • Iaccarino, Guido
  • Lunde, Ida Gjervold
  • Lyon, Alexander R.
  • Pollesello, Piero|||0000-0001-6994-768X
  • Rena, Graham
  • Riksen, Niels P.
  • Rosano, Giuseppe
  • Staels, Bart
  • Van Laake, Linda W.
  • Wanner, Christoph|||0000-0001-9507-5301
  • Farmakis, Dimitrios|||0000-0001-8364-3447
  • Filippatos, Gerasimos|||0000-0002-5640-0332
  • Ruschitzka, Frank
  • Seferovic, Petar
  • de Boer, Rudolf A..
  • Heymans, Stephane
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Persistent chest pain after recovery of COVID-19, microvascular disease-related angina?

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure

  • Teis, Albert|||0000-0002-4820-0736
  • Cediel, Germán|||0000-0001-9667-7507
  • Amigó, Núria|||0000-0002-0116-9145
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Aranyó, Júlia
  • Andrés-Cordón, Joan Francesc|||0000-0003-4264-4499
  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Gual-Capllonch, Francisco
  • Ferrer-Sistach, Elena|||0000-0002-1795-2193
  • Vallejo Camazón, Núria|||0000-0001-6644-6767
  • Juncà Puig, Gladys|||0000-0002-4421-5658
  • López Ayerbe, Jorge|||0009-0008-8495-0877
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Domingo, Mar|||0000-0002-2935-1272
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Codina, Pau|||0000-0002-2469-5711
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Evidence regarding any association of HDL-particle (HDL-P) derangements and HDL-cholesterol content with cardiovascular (CV) death in chronic heart failure (HF) is lacking. To investigate the prognostic value of HDL-P size (HDL-Sz) and the number of cholesterol molecules per HDL-P for CV death in HF patients. Outpatient chronic HF patients were enrolled. Baseline HDL-P number, subfractions and HDL-Sz were measured using 1H-NMR spectroscopy. The HDL-C/P ratio was calculated as HDL-cholesterol over HDL-P. Endpoint was CV death, with non-CV death as the competing event. 422 patients were included and followed-up during a median of 4.1 (0-8) years. CV death occurred in 120 (30.5%) patients. Mean HDL-Sz was higher in CV dead as compared with survivors (8.39 nm vs. 8.31 nm, p < 0.001). This change in size was due to a reduction in the percentage of small HDL-P (54.6% vs. 60% for CV-death vs. alive; p < 0.001). HDL-C/P ratio was higher in the CV-death group (51.0 vs. 48.3, p < 0.001). HDL-Sz and HDL-C/P ratio were significantly associated with CV death after multivariable regression analysis (HR 1.22 [95% CI 1.01-1.47], p = 0.041 and HR 1.04 [95% CI 1.01-1.07], p = 0.008 respectively). HDL-Sz and HDL-C/P ratio are independent predictors of CV death in chronic HF patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Head-to-head comparison of two engineered cardiac grafts for myocardial repair, From scaffold characterization to pre-clinical testing

  • Perea Gil, Isaac
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Jorba, Ignasi
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Roura, Santiago|||0000-0003-4063-9661
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Farré, Ramon|||0000-0002-9084-7824
  • Navajas, Daniel|||0000-0001-7150-9363
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cardiac tissue engineering, which combines cells and supportive scaffolds, is an emerging treatment for restoring cardiac function after myocardial infarction (MI), although, the optimal construct remains a challenge. We developed two engineered cardiac grafts, based on decellularized scaffolds from myocardial and pericardial tissues and repopulated them with adipose tissue mesenchymal stem cells (ATMSCs). The structure, macromechanical and micromechanical scaffold properties were preserved upon the decellularization and recellularization processes, except for recellularized myocardium micromechanics that was ∼2-fold stiffer than native tissue and decellularized scaffolds. Proteome characterization of the two acellular matrices showed enrichment of matrisome proteins and major cardiac extracellular matrix components, considerably higher for the recellularized pericardium. Moreover, the pericardial scaffold demonstrated better cell penetrance and retention, as well as a bigger pore size. Both engineered cardiac grafts were further evaluated in pre-clinical MI swine models. Forty days after graft implantation, swine treated with the engineered cardiac grafts showed significant ventricular function recovery. Irrespective of the scaffold origin or cell recolonization, all scaffolds integrated with the underlying myocardium and showed signs of neovascularization and nerve sprouting. Collectively, engineered cardiac grafts -with pericardial or myocardial scaffolds- were effective in restoring cardiac function post-MI, and pericardial scaffolds showed better structural integrity and recolonization capability.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

  • Pacho Pacho, Cristina
  • Domingo, Mar|||0000-0002-2935-1272
  • Núñez Aragón, Raquel
  • Lupón, Josep|||0000-0002-5601-9611
  • Núñez, Julio|||0000-0003-1672-7119
  • Barallat, Jaume|||0000-0003-3493-5958
  • Moliner, P.|||0000-0002-5511-8597
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Santesmases Ejarque, Javier|||0000-0002-1226-1617
  • Cediel, Germán|||0000-0001-9667-7507
  • Roura, Santiago|||0000-0003-4063-9661
  • Pastor, M. Cruz
  • Tor Aguilera, Jordi|||0000-0002-5355-9110
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Heart failure (HF) is associated with a high rate of readmissions within 30 days post-discharge and in the following year, especially in frail elderly patients. Biomarker data are scarce in this high-risk population. This study assessed the value of early post-discharge circulating levels of ST2, NT-proBNP, CA125, and hs-TnI for predicting 30-day and 1-year outcomes in comorbid frail elderly patients with HF with mainly preserved ejection fraction (HFpEF). Blood samples were obtained at the first visit shortly after discharge (4.9 ± 2 days). The primary endpoint was the composite of all-cause mortality or HF-related rehospitalization at 30 days and at 1 year. All-cause mortality alone at one year was also a major endpoint. HF-related rehospitalizations alone were secondary end-points. From February 2014 to November 2016, 522 consecutive patients attending the STOP-HF Clinic were included (57.1% women, age 82 ± 8.7 years, mean Barthel index 70 ± 25, mean Charlson comorbidity index 5.6 ± 2.2). The composite endpoint occurred in 8.6% patients at 30 days and in 38.5% at 1 year. In multivariable analysis, ST2 [hazard ratio (HR) 1.53; 95% CI 1.19-1.97; p = 0.001] was the only predictive biomarker at 30 days; at 1 year, both ST2 (HR 1.34; 95% CI 1.15-1.56; p < 0.001) and NT-proBNP (HR 1.19; 95% CI 1.02-1.40; p = 0.03) remained significant. The addition of ST2 and NT-proBNP into a clinical predictive model increased the AUC from 0.70 to 0.75 at 30 days (p = 0.02) and from 0.71 to 0.74 at 1 year (p < 0.05). For all-cause death at 1 year, ST2 (HR 1.50; 95% CI 1.26-1.80; p < 0.001), and CA125 (HR 1.41; 95% CI 1.21-1.63; p < 0.001) remained independent predictors in multivariable analysis. The addition of ST2 and CA125 into a clinical predictive model increased the AUC from 0.74 to 0.78 (p = 0.03). For HF-related hospitalizations, ST2 was the only predictive biomarker in multivariable analyses, both at 30 days and at 1 year. In a comorbid frail elderly population with HFpEF, ST2 outperformed NT-proBNP for predicting the risk of all-cause mortality or HF-related rehospitalization. ST2, a surrogate marker of inflammation and fibrosis, may be a better predictive marker in high-risk HFpEF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ex vivo assessment and in vivo validation of non-invasive stent monitoring techniques based on microwave spectrometry

  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Arauz-Garofalo, Gianluca|||0000-0001-5166-6054
  • Rodriguez-Leor, Oriol|||0000-0003-2657-5657
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Amorós García de Valdecasas, Susana
  • Gerez-Britos, Flavio David
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • O'Callaghan, Juan Manuel|||0000-0002-2740-0202
  • Macià, Ferran|||0000-0001-5972-4810
  • Tejada, Javier|||0000-0001-9246-5566
Some conditions are well known to be directly associated with stent failure, including in-stent re-occlusion and stent fracture. Currently, identification of these high-risk conditions requires invasive and complex procedures. This study aims to assess microwave spectrometry (MWS) for monitoring stents non-invasively. Preliminary ex vivo data are presented to move to in vivo validation. Fifteen mice were assigned to receive subcutaneous stent implantations (n = 10) or sham operations (n = 5). MWS measurements were carried out at 0, 2, 4, 7, 14, 22, and 29 days of follow-up. Additionally, 5 stented animals were summited to micro-CT analyses at the same time points. At 29 days, 3 animals were included into a stent fracture subgroup and underwent a last MWS and micro-CT analysis. MWS was able to identify stent position and in-stent stenosis over time, also discerning significant differences from baseline measures (P < 0.001). Moreover, MWS identified fractured vs. non-fractured stents in vivo. Taken together, MWS emerges as a non-invasive, non-ionizing alternative for stent monitoring. MWS analysis clearly distinguished between in-stent stenosis and stent fracture phenomena.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure, A Systematic Review and Meta-Analysis

  • Yang, Xiaobo
  • Lupón, Josep|||0000-0002-5601-9611
  • Vidán, Maria T.
  • Ferguson, Caleb
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Newton, Phillip J.
  • Macdonald, Peter S.
  • Bueno, Héctor|||0000-0003-0277-7596
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Woo, Jean
  • Fung, Erik|||0000-0002-8209-9467
Background: Although frailty has been associated with increased risks for hospitalization and mortality in chronic heart failure, the precise average effect remains uncertain. We performed a systematic review and meta-analysis to summarize the hazards for mortality and incident hospitalization in patients with heart failure and frailty compared with those without frailty and explored the heterogeneity underlying the effect size estimates. Methods and Results: MEDLINE, EMBASE, and Cochrane databases were queried for articles published between January 1966 and March 2018. Predefined selection criteria were used. Hazard ratios () were pooled for meta-analyses, and where odds ratios were used previously, original data were recalculated for . Overlapping data were consolidated, and only unique data points were used. Study quality and bias were assessed. Eight studies were included for mortality (2645 patients), and 6 studies were included for incident hospitalization (2541 patients) during a median follow-up of 1.82 and 1.12 years, respectively. Frailty was significantly associated with an increased hazard for mortality (, 1.54; 95% confidence interval, 1.34-1.75; P <0.001) and incident hospitalization (, 1.56; 95% confidence interval, 1.36-1.78; P <0.001) in chronic heart failure. The Fried phenotype estimated a 16.9% larger effect size than the combined Fried/non-Fried frailty assessment for the end point of mortality (, 1.80; 95% confidence interval, 1.41-2.28; P <0.001), but not for hospitalization (, 1.57; 95% confidence interval, 1.30-1.89; P <0.001). Study heterogeneity was found to be low (I 2 =0%), and high quality of studies was verified by the Newcastle-Ottawa scale. Conclusions: Overall, the presence of frailty in chronic heart failure is associated with an increased hazard for death and hospitalization by ≈1.5-fold.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar, the AGTP II trial

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Cámara, Maria-Luisa|||0000-0002-5204-1459
  • Bustamante-Munguira, Juan|||0000-0002-6542-4504
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Avanzas, Pablo|||0000-0002-4958-6108
  • San Román, José Alberto|||0000-0003-0764-0839
  • Pascual-Figal, DA.|||0000-0002-4993-9540
  • De Teresa, Eduardo
  • Crespo-Leiro, Maria Generosa|||0000-0002-3085-167X
  • Manito, Nicolás
  • Núñez, Julio|||0000-0003-1672-7119
  • Fernández Avilés, Francisco|||0000-0001-5501-5275
  • Caballero, Ángel
  • Teis, Albert|||0000-0002-4820-0736
  • Lupón, Josep|||0000-0002-5601-9611
  • Brugada, Ramon|||0000-0001-6607-3032
  • Martín, Carlos
  • Silva, Jacobo
  • Revilla-Orodea, Ana
  • Cánovas López, Sergio Juan
  • Melero, Jose M.
  • Cuenca Castillo, José
  • Gonzalez-Pinto, Angel
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cardiac adipose tissue is a source of progenitor cells with regenerative capacity. Studies in rodents demonstrated that the intramyocardial delivery of cells derived from this tissue improves cardiac function after myocardial infarction (MI). We developed a new reparative approach for damaged myocardium that integrates the regenerative properties of cardiac adipose tissue with tissue engineering. In the adipose graft transposition procedure (AGTP), we dissect a vascularised flap of autologous pericardial adipose tissue and position it over the myocardial scarred area. Following encouraging results in acute and chronic MI porcine models, we performed the clinical trial (NCT01473433, AdiFLAP trial) to evaluate safety in patients with chronic MI undergoing coronary artery bypass graft. The good safety profile and trends in efficacy warranted a larger trial. The AGTP II trial (NCT02798276) is an investigator initiated, prospective, randomised, controlled, multicentre study to assess the efficacy of the AGTP in 108 patients with non-revascularisable MI. Patients will be assigned to standard clinical practice or the AGTP. The primary endpoint is change in necrotic mass ratio by gadolinium enhancement at 91 and 365 days. Secondary endpoints include improvement in regional contractibility by MRI at 91 and 365 days; changes in functional MRI parameters (left ventricular ejection fraction, left and right ventricular geometric remodelling) at 91 and 365 days; levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) at 7, 91 and 365 days; appearance of arrhythmias from 24 hour Holter monitoring at 24 hours, and at 91 and 365 days; all cause death or re-hospitalisation at 365 days; and cardiovascular death or re-hospitalisation at 365 days. The institutional review board approved the trial which will comply with the Declaration of Helsinki. All patients will provide informed consent. It may offer a novel, effective and technically simple technique for patients with no other therapeutic options. The results will be submitted to indexed medical journals and national and international meetings. ClinicalTrials.gov: NCT02798276, pre-results.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mesenchymal stem cells for cardiac repair, are the actors ready for the clinical scenario?

  • Roura, Santiago|||0000-0003-4063-9661
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Mirabel, Clémentine
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches. We also include the latest advances and future challenges, including good manufacturing practice and regulatory issues. Finally, we evaluate whether recent approaches hold potential for reliable translation to clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic Value of New-Generation Troponins in -Segment-Elevation Myocardial Infarction in the Modern Era, The - Study

  • Cediel, Germán|||0000-0001-9667-7507
  • Rueda, Ferran|||0000-0001-5464-4870
  • Garcia Garcia, Cosme|||0000-0001-6330-1677
  • Oliveras, Teresa
  • Labata, Carlos|||0000-0002-4505-0787
  • Serra Flores, Jordi
  • Núñez, Julio|||0000-0003-1672-7119
  • Bodi, Vicente|||0000-0001-6425-5828
  • Ferrer Massot, Marc|||0000-0003-0046-1301
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
In -segment-elevation myocardial infarction (), troponins are not needed for diagnosis: symptoms and data are sufficient to activate percutaneous coronary intervention. This study explored the prognostic value of new-generation troponins in a real-life cohort contemporarily treated for . We studied 1260 consecutive patients with primary treated with percutaneous coronary intervention between February 22, 2011, and August 31, 2015. We collected data on clinical characteristics and major adverse cardiovascular and cerebrovascular events () at 30 days and 1 year. Peak high-sensitivity troponin T and sensitive-contemporary troponin I levels were recorded. s occurred in 75 patients (6.1%) by day 30 and in 124 patients (10.8%) between day 31 and 1 year. A short-term (0-30 days) multivariable Cox regression analysis revealed that age, Killip-Kimball class, and left ventricular ejection fraction were independent predictors of s. In adjusted analysis, peak high-sensitivity troponin T and sensitive-contemporary troponin I were not significant (hazard ratio, 1.23 [95% confidence interval, 0.98-1.54] [ P =0.071]; and hazard ratio, 1.15 [95% confidence interval, 0.93-1.43] [ P =0.200], respectively). A long-term (31 days-1 year) multivariable Cox regression analysis revealed that age, female sex, diabetes mellitus, prior coronary artery disease, Killip-Kimball class, and left ventricular ejection fraction were statistically significantly associated with . However, peak high-sensitivity troponin T and peak sensitive-contemporary troponin I were not significantly associated with (hazard ratio, 1.03 [95% confidence interval, 0.88-1.20] [ P =0.715]; and hazard ratio, 0.99 [95% confidence interval, 0.85-1.15] [ P =0.856], respectively). In the modern era, new-generation troponins do not provide significant prognostic information for predicting clinical events in . We should reconsider the value of serial troponin measurements for risk stratification in STEMI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In vivo experience with natural scaffolds for myocardial infarction, the times they are a-changin'

  • Perea Gil, Isaac
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Treating a myocardial infarction (MI), the most frequent cause of death worldwide, remains one of the most exciting medical challenges in the 21st century. Cardiac tissue engineering, a novel emerging treatment, involves the use of therapeutic cells supported by a scaffold for regenerating the infarcted area. It is essential to select the appropriate scaffold material; the ideal one should provide a suitable cellular microenvironment, mimic the native myocardium, and allow mechanical and electrical coupling with host tissues. Among available scaffold materials, natural scaffolds are preferable for achieving these purposes because they possess myocardial extracellular matrix properties and structures. Here, we review several natural scaffolds for applications in MI management, with a focus on pre-clinical studies and clinical trials performed to date. We also evaluate scaffolds combined with different cell types and proteins for their ability to promote improved heart function, contractility and neovascularization, and attenuate adverse ventricular remodeling. Although further refinement is necessary in the coming years, promising results indicate that natural scaffolds may be a valuable translational therapeutic option with clinical impact in MI repair.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis

  • Vallejo Camazon, Nuria
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Cediel, Germán|||0000-0001-9667-7507
  • Escolà-Vergé, Laura|||0000-0002-5608-3090
  • Fernández Hidalgo, Nuria|||0000-0002-2115-344X
  • Gurguí, Mercè|||0000-0002-0474-3528
  • Pérez Rodriguez, María Teresa|||0000-0003-2944-8610
  • Cuervo, Guillermo|||0000-0002-7075-943X
  • Núñez Aragón, Raquel
  • Llibre, Cinta|||0000-0003-3618-9741
  • Sopena, Nieves|||0000-0001-6382-9500
  • Quesada, Maria Dolores|||0000-0001-8360-3787
  • Berastegui García, Elisabet|||0000-0002-1766-2970
  • Teis, Albert|||0000-0002-4820-0736
  • López Ayerbe, Jorge|||0009-0008-8495-0877
  • Juncà Puig, Gladys|||0000-0002-4421-5658
  • Gual-Capllonch, Francisco
  • Ferrer Sistach, Elena
  • Vivero, Ainhoa
  • Reynaga, Esteban|||0000-0002-4069-6087
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Muñoz-Guijosa, Christian|||0000-0002-0272-1704
  • Pedro Botet, Maria Luisa|||0000-0001-7252-3191
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Background: To date, there is little information regarding management of patients with infective endocarditis (IE) that did not undergo an indicated surgery. Therefore, we aimed to evaluate prognosis of these patients treated with a long-term antibiotic treatment strategy, including oral long term suppressive antibiotic treatment in five referral centres with a multidisciplinary endocarditis team. Methods: This retrospective, multicenter study retrieved individual patient-level data from five referral centres in Spain. Among a total of 1797, 32 consecutive patients with IE were examined (median age 72 years; 78% males) who had not undergone an indicated surgery, but received long-term antibiotic treatment (LTAT) and were followed by a multidisciplinary endocarditis team, between 2011 and 2019. Primary outcomes were infection relapse and mortality during follow-up. Results: Among 32 patients, 21 had IE associated with prostheses. Of the latter, 8 had an ascending aorta prosthetic graft. In 24 patients, a switch to long-term oral suppressive antibiotic treatment (LOSAT) was considered. The median duration of LOSAT was 277 days. Four patients experienced a relapse during follow-up. One patient died within 60 days, and 12 patients died between 60 days and 3 years. However, only 4 deaths were related to IE. Conclusions: The present study results suggest that a LTAT strategy, including LOSAT, might be considered for patients with IE that cannot undergo an indicated surgery. After hospitalization, they should be followed by a multidisciplinary endocarditis team.